TABLE 36-1
Components of the Hemostatic System
(continued)
Associated Disease(s)
Concentration
Tissue
PDB
Common
Hemorrhagic/
Disease
in Plasma 3
Source/Half-life (hr)
Codes for
SwissProt
Name1
Thrombotic Risk
Prevalence
mg/L
jUM
Proteins 4
Designations 4
Fibrinolytic System Components
Proteinase Precursors
Malignant tumors have high
concentrations of fibrinolytic system
components
Plasminogen
2 0 0
1.5-2
Liver
53
ICE A, 1CEB,
1HPJ, 1HPK,
1HTN, 5HPG
PLMNJHUMAN
Tissue plasminogen activator
80 x
1 0 - 6
Endothelial cells
1PK2, 1PK4,
UROTJBUMAN
(t-PA)
~ 5
min
1PKR, 1PMK
1PML, 1RTF,
1TPG, 1TPK,
1TPM, TPN,
2PK4
Urinary plasminogen activator
150 x lO
^ 6
~1 min
1KDU,
UROKJHUMAN
(scu-PA)
0.04
1LMW,
1URK
Proteinase Inhibitors
a-2
Antiplasmin
Bleeding, usually hours after
Extremely
Liver
62
A2AP_HUMAN
Plasma
hemostasis (re-bleeding) due to
rare
70
1
Platelets
premature digestion of the fibrin
0.09
(a-2 AP)
a
- 2
plasmin inhibitor
in the hemostatic plug
a-2
Macroglobulin
2,500
3.5
Liver
A2MG_ HUMAN
(a-2 M)
PAI-1
Elevated in disease (acute phase
Septicemia
Endothelium,
PAI1JTUMAN
Plasma
reactant), elevation related to
-elevated
0 . 0 2
0.0004
9
Liver
~7 min
Platelets
DVT, deficiency results in
bleeding. Rises during pregnancy
in 3rd trimester),
elevated
in
pre-eclampsia
PAI-1
1.4
(continued)
